Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. XOMA
XOMA logo

XOMA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Xoma Royalty Corp (XOMA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
41.890
1 Day change
1.45%
52 Week Range
42.810
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Xoma Royalty Corp (XOMA) is not a strong buy for a beginner investor with a long-term focus at this moment. While the stock has a bullish moving average trend and a positive long-term price target from analysts, the lack of significant trading signals, weak financial performance in the latest quarter, and neutral sentiment from hedge funds and insiders suggest that it is better to hold off on investing right now.

Technical Analysis

The stock shows a bullish moving average trend (SMA_5 > SMA_20 > SMA_200), but the MACD is negatively expanding (-0.0436) and RSI is neutral at 46.226. Key support and resistance levels are S1: 36.648, Pivot: 38.543, and R1: 40.438. The pre-market price of $37.8 is close to the support level, indicating limited upside in the short term.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
2
Buy
10

Positive Catalysts

  • Analysts have raised the price target to $50 from $45 with an Outperform rating. The stock has a 5.75% chance of increasing in the next month based on historical patterns.

Neutral/Negative Catalysts

  • The company's financials for Q4 2025 show a significant drop in net income (-162.29% YoY) and EPS (-157.78% YoY). No recent news or significant trading activity from hedge funds, insiders, or Congress. The MACD and RSI indicators do not suggest strong momentum.

Financial Performance

In Q4 2025, revenue increased by 57.87% YoY to $13.76M, but net income dropped significantly by -162.29% YoY to $3.32M. EPS also declined by -157.78% YoY to 0.26. Gross margin remained stable at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Leerink raised the price target to $50 from $45 and maintained an Outperform rating, indicating positive long-term sentiment.

Wall Street analysts forecast XOMA stock price to rise
5 Analyst Rating
Wall Street analysts forecast XOMA stock price to rise
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 41.290
sliders
Low
50
Averages
71
High
97
Current: 41.290
sliders
Low
50
Averages
71
High
97
H.C. Wainwright
Joseph Pantginis
Buy -> Neutral
downgrade
$39
AI Analysis
2026-04-30
Reason
H.C. Wainwright
Joseph Pantginis
Price Target
$39
AI Analysis
2026-04-30
downgrade
Buy -> Neutral
Reason
H.C. Wainwright analyst Joseph Pantginis downgraded Xoma to Neutral from Buy with a $39 price target citing the pending acquisition by Ligand.
Lucid Capital
Elemer Piros
Buy
to
Neutral
downgrade
$66 -> $39
2026-04-27
Reason
Lucid Capital
Elemer Piros
Price Target
$66 -> $39
2026-04-27
downgrade
Buy
to
Neutral
Reason
Lucid Capital analyst Elemer Piros downgraded Xoma (XOMA) to Neutral from Buy with a price target of $39, down from $66, after Ligand Pharmaceuticals (LGND) announced a definitive agreement to acquire Xoma for $39 per share in cash.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for XOMA
Unlock Now

People Also Watch